Recce Pharmaceuticals Ltd reported earnings results for the half year ended December 31, 2023. For the half year, the company reported revenue was AUD 2.42 million compared to AUD 0.038823 million a year ago. Net loss was AUD 7.46 million compared to AUD 9.22 million a year ago.

Basic loss per share from continuing operations was AUD 0.0416 compared to AUD 0.0526 a year ago. Diluted loss per share from continuing operations was AUD 0.0416 compared to AUD 0.0526 a year ago.